Clinical utility of labeled cells for detection of allograft rejection and myocardial infarction.
The choice of a specific radiolabeled blood component for use in detection of allograft rejection depends on several factors including the immunosuppressive agents used, the type of organ allografted, and particularly the length of time the allograft resides in the host and the duration of rejection. To date, only the use of 111In-labeled platelets in renal allograft recipients immunosuppressed with azathioprine and corticosteroids has shown clinical promise in the detection of early allograft rejection. Radiolabeled blood components are unlikely to play a significant role in detection of myocardial infarction. The use of these agents for monitoring therapeutic interventions or as indicators of prognosis in patients with myocardial infarction continues to be investigated.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D001379:Azathioprine / Q000627:therapeutic use; D001792:Blood Platelets; D003524:Cyclosporins / Q000627:therapeutic use; D006084:Graft Rejection; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007204:Indium; D016030:Kidney Transplantation; D007962:Leukocytes; D009203:Myocardial Infarction / Q000000981:diagnostic imaging*; D009504:Neutrophils; D011868:Radioisotopes; D011877:Radionuclide Imaging; D051381:Rats
D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D007166:Immunosuppressive Agents; D011868:Radioisotopes; D007204:Indium; D001379:Azathioprine